TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30824645

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 300
Study: 30825104

Group type: EXPERIMENTAL
Intervention: Pexidartinib 600 mg/d
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pexidartinib 1000 mg/d for 2 weeks, then 800 mg/d thereafter
Number of subjects: 11
Study: 30825970

Group type: EXPERIMENTAL
Intervention: Concurrent SBRT (40 Gy) and nelfinavir (1250 mg BID for 5 weeks)
Number of subjects: 46
Study: 30826071

Group type: EXPERIMENTAL
Intervention: Deletion genotype (n = 37)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nondeletion genotype (n = 21)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both genotypes
Number of subjects: 106
Study: 30826192

Group type: EXPERIMENTAL
Intervention: COMBO stent
Number of subjects: 2614
Study: 30826465

Group type: EXPERIMENTAL
Intervention: Bortezomib added to rituximab (R) plus BEAM regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab (R) plus BEAM regimen without bortezomib
Number of subjects: 0
Study: 30826528

Group type: EXPERIMENTAL
Intervention: Acute culprit lesion (Group A)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Stable obstructive coronary disease (Group B)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Non-obstructive or absent coronary disease (Group C)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Admission cTnI > 0.46 ng/mL with STEMI present in ECG
Number of subjects: 159
Study: 30826767

Group type: EXPERIMENTAL
Intervention: Dual-layer spectral detector CT (SDCT) including static stress CT perfusion (CTP)
Number of subjects: 75
Study: 30826792

Group type: EXPERIMENTAL
Intervention: HEAL-D culturally tailored diabetes self-management programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 30826789

Group type: EXPERIMENTAL
Intervention: CPSP development
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Functional status and cost of illness
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Quality-adjusted life years (QALYs)
Number of subjects: 1250
Study: 30827133

Group type: EXPERIMENTAL
Intervention: Hypertension (uncontrolled)
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Hypertension (medically treated but uncontrolled)
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Hypertension (treated and controlled)
Number of subjects: 1673

Group type: COMPARATOR
Intervention: Normotension
Number of subjects: 1673
Study: 30827193

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 237
Study: 30827933

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating inflammatory cytokines (LDH, sIL-2R, TNF-α, decreased LMR)
Number of subjects: 228

Group type: COMPARATOR
Intervention: International Prognostic Index (IPI)
Number of subjects: 228

Group type: COMPARATOR
Intervention: NCCN-IPI
Number of subjects: 228
Study: 30828313

Group type: EXPERIMENTAL
Intervention: IL-6 Plasma Levels
Number of subjects: 0
Study: 30828456

Group type: EXPERIMENTAL
Intervention: Initial impression of the attending physician
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial impression of the site investigator
Number of subjects: 0
Study: 30829754

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (Bellafill)
Number of subjects: 42
Study: 30829829

Group type: EXPERIMENTAL
Intervention: Advance care planning intervention
Number of subjects: 30
Study: 30830538

Group type: EXPERIMENTAL
Intervention: Skin-sparing mastectomy (SSM)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nipple-sparing mastectomy (NSM)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall (SSM and NSM)
Number of subjects: 160
Study: 30830886

Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panobinostat (PNB)
Number of subjects: 0
Study: 30831104

Group type: EXPERIMENTAL
Intervention: Early insertion (days 1-7 from last menstrual period)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Recent hormonal contraceptive use
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Early insertion
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Recent contraceptive use
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 125

Group type: COMPARATOR
Intervention: Late insertion (remainder of menstrual cycle)
Number of subjects: 125
Study: 30832571

Group type: EXPERIMENTAL
Intervention: Triage- and risk stratification scores, clinical impression scores, laboratory tests
Number of subjects: 0
Study: 30832577

Group type: EXPERIMENTAL
Intervention: Medically managed patients in a structured management program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Surgically treated patients
Number of subjects: 186
Study: 30832606

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg administered every 2 weeks up to 24 months or until confirmed progression or intolerable toxicity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 22
Study: 30832636

Group type: EXPERIMENTAL
Intervention: Persona Knee Implant System
Number of subjects: 146
Study: 30832656

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) for detection of intraplaque hemorrhage (IPH)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced (DCE)-CMR for assessment of plaque microvasculature
Number of subjects: 132
Study: 30832720

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole, trimethoprim and guaifenesin (STG)
Number of subjects: 103
Study: 30832732

Group type: EXPERIMENTAL
Intervention: α-PD-1 therapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: α-TGFβ monotherapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: α-PD-1 and α-TGFβ combinatorial therapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: α-TGFβ antibody administration
Number of subjects: 6
Study: 30833313

Group type: EXPERIMENTAL
Intervention: Measures of obesity, functional capacity and exercise capacity assessments, quality of life questionnaires, and blood and tissue sampling for biomarker analysis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers of interest focusing on metabolism (lipids, amino acids) and inflammation (adipokines, cytokines, and chemokines).
Number of subjects: 0
Study: 30833368

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1000
Study: 30833370

Group type: EXPERIMENTAL
Intervention: Higher mean glycemic exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline and time-dependent glycemic and nonglycemic risk factors
Number of subjects: 0
Study: 30833417

Group type: EXPERIMENTAL
Intervention: Biallelic mutations in base excision repair genes
Number of subjects: 1
Study: 30833442

Group type: EXPERIMENTAL
Intervention: Carboplatin treatment with hypersensitivity reaction management
Number of subjects: 860

Group type: COMPARATOR
Intervention: Non-hypersensitivity reaction group
Number of subjects: 860
Study: 30833489

Group type: EXPERIMENTAL
Intervention: Merestinib (120 mg once daily)
Number of subjects: 186
Study: 30833915

Group type: EXPERIMENTAL
Intervention: Brief Parent Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30834280

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (Progen) containing hydrolyzed collagen peptides, plasma proteins, hyaluronic acid-chondroitin sulfate complex, and vitamin C
Number of subjects: 72

Group type: COMPARATOR
Intervention: No additional therapy (control group)
Number of subjects: 72
Study: 30834940

Group type: EXPERIMENTAL
Intervention: sunitinib 37.5 mg/day on a continuous daily dosing schedule
Number of subjects: 12
Study: 30834972

Group type: EXPERIMENTAL
Intervention: SiCaP EP (Inductigraft™, Altapore) used as bone grafting material in PLF surgery
Number of subjects: 102
Study: 30835255

Group type: EXPERIMENTAL
Intervention: De novo synthesized neoantigen-loaded dendritic cell vaccines
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Shared neoantigen peptide library
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Personalized immunotherapy
Number of subjects: 6
Study: 30835533

Group type: EXPERIMENTAL
Intervention: CLAIR index (AI-linked continuous glucose monitoring)
Number of subjects: 50
Study: 30836314

Group type: EXPERIMENTAL
Intervention: Safingol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All-trans-N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR)
Number of subjects: 0
Study: 30836948

Group type: EXPERIMENTAL
Intervention: Higher pre-dialysis serum magnesium concentration
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration > 2.5 mEq/L
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intradialytic volume and potassium removal
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intravenous potassium and weight change
Number of subjects: 66
Study: 30836953

Group type: EXPERIMENTAL
Intervention: Optimal management of six modifiable haemodialysis practices
Number of subjects: 0
Study: 30836994

Group type: EXPERIMENTAL
Intervention: Contacted individually
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Contacted face-to-face
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Signed collaboration agreement
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Completed baseline questionnaire
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Dropout rate
Number of subjects: 4065
Study: 30837247

Group type: EXPERIMENTAL
Intervention: Overuse of medical interventions (commission errors) in primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost analysis of overuse
Number of subjects: 0
Study: 30837503

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus cisplatin (AP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: nab-paclitaxel plus gemcitabine (AG)
Number of subjects: 73
Study: 30837835

Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30838348

Group type: EXPERIMENTAL
Intervention: Diet low in fermentable carbohydrates (FODMAPs)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Diet records for 4 consecutive days
Number of subjects: 197
Study: 30839493

Group type: EXPERIMENTAL
Intervention: Systemic hormone therapy (HT) prescriptions
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: New prescriptions for systemic HT
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Renewal prescriptions for systemic HT
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Renewal prescriptions with conjugated equine estrogen doses ≥0.625 mg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Prescriptions for systemic estrogen in women with a uterus
Number of subjects: 116
Study: 30840064

Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFIRI
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wild-type patients (no mutations)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patients with RAS (KRAS/NRAS) mutations
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patients with RAS/BRAF mutations
Number of subjects: 72
Study: 30840757

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (4000 units daily for 2 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study: 30840787

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg) for 8 weeks (Phase 1)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg) continued for responders, adjunctive aripiprazole (2-10 mg) for nonresponders for a further 8 weeks (Phase 2)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: LEAPS (Lam Employment Absence and Productivity Scale)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Early symptomatic improvement
Number of subjects: 211
Study: 30841510

Group type: EXPERIMENTAL
Intervention: Microfat-PRP ATMP
Number of subjects: 3
Study: 30842026

Group type: EXPERIMENTAL
Intervention: Race duration
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) at baseline
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Cardiac TnI concentrations
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: cTnT concentrations
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: cTnI assay
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: cTnT assay
Number of subjects: 1002
Study: 30842122

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study: 30843005

Group type: EXPERIMENTAL
Intervention: Fluorine-18-fluorodexoglucose quantification
Number of subjects: 123
Study: 30843056

Group type: EXPERIMENTAL
Intervention: Clinical Decision Guideline (CDG) for influenza testing
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: CDG scoring system (score of ≥3 indicates testing warranted)
Number of subjects: 1941
Study: 30843107

Group type: EXPERIMENTAL
Intervention: Increased salt iodine concentration from 20 to 25 mg/kg
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Control group (previous iodine concentration of 20 mg/kg)
Number of subjects: 1447
Study: 30843160

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily
Number of subjects: 21
Study: 30843184

Group type: EXPERIMENTAL
Intervention: Bone marrow transplant (BMT) with post-transplant cyclophosphamide (PTCy)
Number of subjects: 10
Study: 30843659

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (5, 10, 15, or 20 mg BID for 3 weeks out of five for seven cycles) combined with Ibrutinib (420 mg daily)
Number of subjects: 12
Study: 30844465

Group type: EXPERIMENTAL
Intervention: Shorter telomere length (TL)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Internalizing psychopathology at 8 to 10 years
Number of subjects: 195
Study: 30845873

Group type: EXPERIMENTAL
Intervention: β-Blockers
Number of subjects: 720

Group type: COMPARATOR
Intervention: Persistent heart failure with reduced ejection fraction (HF r EF)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Low- or high-dose β-blockers
Number of subjects: 720
Study: 30845917

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 641
Study: 30845934

Group type: EXPERIMENTAL
Intervention: Lower HDL-C levels
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: HDL-C levels in a single model
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: HDL-C levels with additional controls for cerebrovascular disease and coronary heart disease
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Elevated triglycerides (TG)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Elevated triglycerides (TG) with remaining 4 MetS components
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Presence of MetS and its components (obesity, reduced HDL-C, elevated glucose, elevated blood pressure)
Number of subjects: 202
Study: 30845939

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 10 Gy prescribed at a 5-mm depth of the tumor bed
Number of subjects: 42
Study: 30845938

Group type: EXPERIMENTAL
Intervention: Integrated panel of airway and blood-based molecular biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biospecimens including nasal brushings, serum, plasma, and intrathoracic airway samples
Number of subjects: 0
Study: 30845960

Group type: EXPERIMENTAL
Intervention: EMONO
Number of subjects: 12
Study: 30845970

Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) measurement
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR) increase
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Gender (male vs female)
Number of subjects: 137
Study: 30845997

Group type: EXPERIMENTAL
Intervention: Three servings (28.3 g each) of sun dried raisins daily for 14 days
Number of subjects: 13
Study: 30846083

Group type: EXPERIMENTAL
Intervention: Transcaval access using Amplatzer nitinol cardiac occluders
Number of subjects: 100
Study: 30846089

Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-coated balloon treatment
Number of subjects: 1535
Study: 30846271

Group type: EXPERIMENTAL
Intervention: FDG Positron Emission Tomography (PET)
Number of subjects: 0
Study: 30846327

Group type: EXPERIMENTAL
Intervention: 16α-
Number of subjects: 93
Study: 30846367

Group type: EXPERIMENTAL
Intervention: Bulimia Nervosa (BN) group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 62
Study: 30846408

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 0
Study: 30846500

Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×10^9/L)
Number of subjects: 0
Study: 30847861

Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: PCOS women with WHR > 0.85
Number of subjects: 109
Study: 30848549

Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 64
Study: 30848695

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Dry Powder for Inhalation
Number of subjects: 0
Study: 30849082

Group type: EXPERIMENTAL
Intervention: Reduced disposition index (DI)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: D2/3R BPND measured by PET scanning
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5-hour oral glucose tolerance test to measure DI by OMM
Number of subjects: 26
Study: 30849383

Group type: EXPERIMENTAL
Intervention: Contemporary cTnI testing
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: High-sensitivity cTnI (hs-cTnI) testing
Number of subjects: 919

Group type: COMPARATOR
Intervention: Cardiologists' classification of cTnI orders
Number of subjects: 919

Group type: COMPARATOR
Intervention: Cardiologists' classification of hs-cTnI orders
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Contemporary cTnI testing for type 1 myocardial infarction
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Contemporary cTnI testing for type 2 myocardial infarction
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Contemporary cTnI testing for myocardial injury
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: High-sensitivity cTnI testing for type 1 myocardial infarction
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: High-sensitivity cTnI testing for type 2 myocardial infarction
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: High-sensitivity cTnI testing for myocardial injury
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Discordance in appropriateness adjudication forms
Number of subjects: 919
Study: 30849758

Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 362

Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 362
Study: 30850011

Group type: EXPERIMENTAL
Intervention: 5 mg tamoxifen
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10 mg tamoxifen
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall (both dosages)
Number of subjects: 21
Study: 30850297

Group type: EXPERIMENTAL
Intervention: Endurant II/IIs endograft in conjunction with Heli-FX EndoAnchor implants (ESAR)
Number of subjects: 70
Study: 30850312

Group type: EXPERIMENTAL
Intervention: Well-child visits screening
Number of subjects: 3475

Group type: COMPARATOR
Intervention: Acute-care visits screening
Number of subjects: 3475

Group type: COMPARATOR
Intervention: Acute-care visits only
Number of subjects: 3475
Study: 30850381

Group type: EXPERIMENTAL
Intervention: Venetoclax plus R-CHOP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Venetoclax plus G-CHOP
Number of subjects: 56

Group type: COMPARATOR
Intervention: G-CHOP (control)
Number of subjects: 56
Study: 30850416

Group type: EXPERIMENTAL
Intervention: Exercisers (11 men and 1 woman)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-exercisers (14 men and 3 women)
Number of subjects: 29
Study: 30850562

Group type: EXPERIMENTAL
Intervention: Endostatin and oxaliplatin (OHP) administered intravenously at doses of 7.5 mg/m², with radiotherapy delivered at a daily fraction of 2.0 Gy to a total dose of 60.0 Gy over 6 weeks.
Number of subjects: 37
Study: 30851070

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1377
Study: 30851221

Group type: EXPERIMENTAL
Intervention: Youths with BD
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Adults with BD
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy youths
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 108
Study: 30852126

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 3.73 ± 1.72 mg) for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control subjects (healthy matched controls)
Number of subjects: 42
Study: 30852540

Group type: EXPERIMENTAL
Intervention: eHealth-based 12-week physical activity programme using a Fitbit activity tracker, remotely prescribed and monitored by a physiotherapist.
Number of subjects: 60
Study: 30852546

Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) evaluation using offline and online technologies including proton transfer reaction mass spectrometry, gas chromatography ion mobility spectrometry, atmospheric pressure chemical ionisation-mass spectrometry, gas chromatography mass spectroscopy, and comprehensive two-dimensional gas chromatography-mass spectrometry.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised blood biomarkers including C reactive protein, brain-derived natriuretic peptide, troponin-I, and blood eosinophil levels.
Number of subjects: 0
Study: 30852561

Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (CryoTBB)
Number of subjects: 61
Study: 30852587

Group type: EXPERIMENTAL
Intervention: Lifelong HIV
Number of subjects: 66

Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 66
Study: 30852604

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 4687

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4687

Group type: EXPERIMENTAL
Intervention: Women aged 18-25
Number of subjects: 4687
Study: 30852767

Group type: EXPERIMENTAL
Intervention: Upper abdominal pain severity assessed by PAGI-SYM
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Increased upper abdominal pain severity
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Abdominal pain prevalence
Number of subjects: 346